Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study

Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study

The cytolethal distending toxin (CDT), <i>Haemophilus ducreyi</i>, is one of the bacterial toxins that have recently been considered for targeted therapies, especially in cancer therapies. CDT is an A-B2 exotoxin. Its catalytic subunit (CdtB) is capable of inducing DNA double strand brea...

Full description

Bibliographic Details
Main Authors: Maryam Keshtvarz, Mahdieh Mahboobi, Marek Kieliszek, Antoni Miecznikowski, Hamid Sedighian, Milad Rezaei, Mohammad Ali Haghighi, Zahra Zareh, Ehsan Rezaei
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Toxins
Subjects:
cytolethal distending toxin
immunogenicity
stability
tumor therapy
mutation
Online Access:https://www.mdpi.com/2072-6651/13/11/785

Internet

https://www.mdpi.com/2072-6651/13/11/785

Similar Items